Semaglutide (GLP-S) (Research Use Only)
Chemical Name: Semaglutide
CAS Number:
910463-68-2
Molecular Formula:
C187H291N45O59
Molecular Weight: 4113.64 g/mol
Sequence: H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-(AEEAc-AEEAc-Gamma-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH
Appearance: White to off-white lyophilized powder
Storage: Store at −20°C
Form: Lyophilized powder; soluble in DMSO (3 mg/mL, 0.73 mM)
Description
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist extensively researched for its glucose-dependent insulin secretagogue activity and appetite suppression. It displays extended half-life due to structural modifications, making it suitable for once-weekly dosing studies. Semaglutide significantly improves glycemic control and promotes weight loss in metabolic disorder models.
(Wikipedia)
(DrugBank)
Research Applications
- Investigation of glycemic regulation in Type 2 diabetes mellitus (T2DM) models
- Study of appetite suppression and obesity-related weight loss
- Pharmacokinetic and pharmacodynamic profiling for long-acting peptides
- Evaluation of cardiovascular risk factor modulation
- Preclinical and clinical efficacy and safety studies
Key Studies & Resources
Mechanism of Action
Semaglutide activates GLP-1 receptors, potentiating glucose-dependent insulin secretion, inhibiting glucagon release, delaying gastric emptying, and reducing appetite signals. These effects culminate in improved glucose control and weight reduction observed in experimental models.
(DrugBank)
Safety and Handling
Store the lyophilized Semaglutide peptide at −20°C. Reconstitute immediately prior to laboratory use. Common mild adverse effects observed include gastrointestinal discomfort and transient injection site reactions in research models.
Disclaimer
For laboratory research use only. Not for human, medical, veterinary, or diagnostic application. This information is provided for scientific, research, and educational purposes only.



